Get the Stockscreener App
0.2925
3.53%
-0.0107
After Hours:
.29
-0.0025
-0.85%
Processa Pharmaceuticals Inc Stock (PCSA) Forecast
The Processa Pharmaceuticals Inc (PCSA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $55.70, representing a +18,943% increase from the current price of $0.2925. The highest analyst price target is $82.39, and the lowest is $29.01.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month PCSA Price Target
Average 41.24
(+13,998% Upside)
Is Processa Pharmaceuticals Inc (PCSA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 57.25 | Neutral |
| STOCH(9,6) | 55.92 | Neutral |
| STOCHRSI(14) | 84.33 | Sell |
| MACD(12,26) | 0.000734 | Buy |
| ADX(14) | 29.22 | Buy |
| William %R | -41.91 | Neutral |
| CCI(14) | 185.57 | Buy |
Buy: 3
Sell: 1
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.2617
Buy
|
0.2702
Buy
|
| MA20 |
0.2538
Buy
|
0.263
Buy
|
| MA50 |
0.2822
Buy
|
0.3136
Sell
|
| MA100 |
0.4514
Sell
|
0.4882
Sell
|
| MA200 |
0.8319
Sell
|
1.0319
Sell
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, PCSA could be considered a Potential Buy, with 17 technical analysis indicators signaling 8 Buy signals, 6 signaling Sell signals and 3 Neutral signals. This might be a good time to open fresh positions on PCSA, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 57.25 indicates that PCSA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 55.92 indicates that PCSA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 84.33 indicates that PCSA is oversold. This suggests that PCSA price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 29.22 suggests a moderate trend in the market. While not exceptionally strong, it indicates that there is some directional movement occurring. You should pay attention to this trend but may also look for confirmation from other technical indicators or fundamental factors.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 185.57 indicates that PCSA is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term PCSA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Processa Pharmaceuticals Inc financial reports and earnings history, Processa Pharmaceuticals Inc (PCSA) stock could reach $47.14 by 2030, $32.92 by 2040 and $291.65 by 2050. See the projected annual prices until 2050 of the Processa Pharmaceuticals Inc stock below:
- Processa Pharmaceuticals Inc (PCSA) is expected to reach an average price of $78.30 in 2035, with a high prediction of $77.93 and a low estimate of $77.89. This indicates an $26,670% rise from the last recorded price of $0.2925.
- Processa Pharmaceuticals Inc (PCSA) stock is projected to chart a bullish course in 2040, with an average price target of $32.02, representing an $10,846% surge from its current level. The forecast ranges from a conservative $32.19 to a sky-high $32.92.
- Our analysts predict Processa Pharmaceuticals Inc (PCSA) to jump 103.85K% by 2045, soaring from $303.66 to an average price of $304.04, potentially reaching $302.70. While $303.66 is the low estimate, the potential upside is significant.
- Processa Pharmaceuticals Inc (PCSA) stock is expected to climb by 2050, reaching an average of $301.05, a $102.82K% jump from its current level. However, a wide range of estimates exists, with high and low targets of $291.65 and $301.09, respectively, highlighting the market's uncertainty.
Processa Pharmaceuticals Inc Stock (PCSA) Year by Year Forecast
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2025
Processa Pharmaceuticals Inc Stock (PCSA) is expected to reach an average price of $59.61 in 2025, with a high prediction of $115.19 and a low estimate of $4.0321. This indicates an +20,280% rise from the last recorded price of $0.2925.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| July, 2025 | $34.81 | $29.01 | $82.39 | +11,800% |
| August, 2025 | $39.02 | $17.30 | $49.82 | +13,240% |
| September, 2025 | $10.23 | $4.0321 | $46.62 | +3,398% |
| October, 2025 | $15.25 | $6.2439 | $34.24 | +5,113% |
| November, 2025 | $11.66 | $6.2586 | $30.85 | +3,886% |
| December, 2025 | $12.02 | $7.0645 | $28.07 | +4,008% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2026
The predicted value for Processa Pharmaceuticals Inc (PCSA) in 2026 is set at an average of $15.65. Estimates vary from a peak of $31.22 to a trough of $0.0822, indicating an +5,251% surge from the present price of $0.2925.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $13.91 | $0.0822 | $16.68 | +4,657% |
| February, 2026 | $10.78 | $1.0939 | $14.91 | +3,584% |
| March, 2026 | $9.3087 | $3.3028 | $24.50 | +3,082% |
| April, 2026 | $17.12 | $8.1146 | $31.22 | +5,754% |
| May, 2026 | $16.64 | $14.73 | $23.33 | +5,587% |
| June, 2026 | $3.947 | $1.447 | $18.94 | +1,249% |
| July, 2026 | $2.9617 | $1.4501 | $12.75 | +912.54% |
| August, 2026 | $4.5735 | $0.7646 | $12.94 | +1,464% |
| September, 2026 | $1.0582 | $0.6147 | $6.3764 | +261.78% |
| October, 2026 | $11.80 | $2.4089 | $9.60 | +3,934% |
| November, 2026 | $15.69 | $10.79 | $13.69 | +5,264% |
| December, 2026 | $17.38 | $16.97 | $16.38 | +5,840% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Processa Pharmaceuticals Inc (PCSA) is $9.7003, with a high forecast of $19.16 and a low forecast of $0.239. This indicates an +3,216% increase from the last price of $0.2925.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $19.98 | $17.15 | $19.16 | +6,730% |
| February, 2027 | $16.94 | $17.94 | $18.27 | +5,691% |
| March, 2027 | $14.54 | $13.88 | $14.16 | +4,870% |
| April, 2027 | $13.89 | $12.12 | $12.41 | +4,648% |
| May, 2027 | $13.05 | $13.11 | $12.12 | +4,362% |
| June, 2027 | $12.30 | $12.42 | $12.33 | +4,104% |
| July, 2027 | $11.99 | $12.29 | $12.09 | +3,997% |
| August, 2027 | $12.07 | $12.47 | $11.28 | +4,026% |
| September, 2027 | $8.0386 | $8.8586 | $10.67 | +2,648% |
| October, 2027 | $4.0469 | $5.8469 | $7.2557 | +1,284% |
| November, 2027 | $2.4649 | $0.239 | $5.5649 | +742.71% |
| December, 2027 | $5.3203 | $4.5132 | $3.4753 | +1,719% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2028
In 2028, Processa Pharmaceuticals Inc (PCSA) is projected to reach an average price of $65.12, with a high projection of $129.77 and a low estimate of $0.4792. This indicates an +22,164% rise from the last price of $0.2925.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $5.7186 | $6.1186 | $5.8815 | +1,855% |
| February, 2028 | $4.1368 | $4.1868 | $5.1056 | +1,314% |
| March, 2028 | $1.792 | $2.332 | $3.5738 | +512.67% |
| April, 2028 | $0.7903 | $0.9903 | $2.0691 | +170.18% |
| May, 2028 | $84.14 | $0.4792 | $84.15 | +28,667% |
| June, 2028 | $29.12 | $38.32 | $60.54 | +9,855% |
| July, 2028 | $32.00 | $16.11 | $27.10 | +10,839% |
| August, 2028 | $25.07 | $32.08 | $27.17 | +8,469% |
| September, 2028 | $58.76 | $6.254 | $110.16 | +19,988% |
| October, 2028 | $64.58 | $50.26 | $129.77 | +21,979% |
| November, 2028 | $14.21 | $10.80 | $78.19 | +4,758% |
| December, 2028 | $23.17 | $16.20 | $17.42 | +7,820% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2029
The 2029 price forecast for Processa Pharmaceuticals Inc Stock (PCSA) is $25.48 on average, with a high prediction of $50.57 and a low estimate of $0.3817. This represents an +8,610% increase from the previous price of $0.2925.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $21.66 | $14.55 | $35.86 | +7,306% |
| February, 2029 | $1.0874 | $9.4756 | $31.07 | +271.77% |
| March, 2029 | $27.09 | $21.91 | $22.69 | +9,161% |
| April, 2029 | $16.33 | $1.4654 | $19.93 | +5,484% |
| May, 2029 | $24.16 | $6.1404 | $50.57 | +8,161% |
| June, 2029 | $13.79 | $0.3817 | $37.39 | +4,614% |
| July, 2029 | $12.79 | $6.5955 | $20.19 | +4,272% |
| August, 2029 | $19.96 | $21.36 | $17.77 | +6,724% |
| September, 2029 | $47.14 | $29.75 | $33.06 | +16,015% |
| October, 2029 | $40.11 | $40.32 | $39.13 | +13,612% |
| November, 2029 | $42.08 | $40.09 | $33.68 | +14,287% |
| December, 2029 | $36.66 | $44.66 | $42.67 | +12,433% |
Processa Pharmaceuticals Inc Stock (PCSA) Price Forecast for 2030
Processa Pharmaceuticals Inc Stock (PCSA) is expected to reach an average price of $35.61 in 2030, with a high forecast of $47.42 and a low forecast of $23.81. This signifies an +12,075% surge from the last price of $0.2925.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $64.03 | $42.45 | $47.14 | +21,791% |
| February, 2030 | $37.73 | $46.01 | $47.42 | +12,798% |
| March, 2030 | $37.58 | $38.20 | $34.59 | +12,749% |
| April, 2030 | $17.56 | $23.81 | $30.58 | +5,903% |
| May, 2030 | $26.63 | $26.14 | $22.35 | +9,004% |
| June, 2030 | $37.71 | $32.52 | $27.32 | +12,791% |
| July, 2030 | $36.68 | $36.89 | $34.89 | +12,439% |
| August, 2030 | $33.45 | $34.46 | $32.66 | +11,337% |
| September, 2030 | $34.93 | $36.85 | $34.54 | +11,842% |
| October, 2030 | $46.20 | $38.02 | $44.00 | +15,695% |
| November, 2030 | $48.48 | $44.39 | $46.48 | +16,473% |
| December, 2030 | $48.35 | $48.55 | $46.18 | +16,431% |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):